Synergy Pharmaceuticals Inc. (SGYP) announced Wednesday morning that both plecanatide 3.0 mg and 6.0 mg doses met the primary endpoint of its phase 3 clinical trial and demonstrated statistical significance in patients with chronic idiopathic constipation.
Synergy Pharmaceuticals has gapped open sharply higher this morning and is now up 1.61 at $6.25 on strong volume. The stock has jumped to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News